PharmaCyte Biotech, Inc. - FORM 10-K - EX-32.1 - CERTIFICATION - August 4, 2014

Attached files

file filename
10-K - FORM 10-K - PharmaCyte Biotech, Inc.nuvilex_10k-043014.htm
EX-10.6 - CONSULTING AGREEMENT - PharmaCyte Biotech, Inc.nuvilex_10k-ex1006.htm
EX-10.9 - MEMORANDUM OF UNDERSTANDING - PharmaCyte Biotech, Inc.nuvilex_10k-ex1009.htm
EX-10.4 - MANUFACTURING FRAMEWORK AGREEMENT - PharmaCyte Biotech, Inc.nuvilex_10k-ex1003.htm
EX-10.10 - EMPLOYMENT AGREEMENT - PharmaCyte Biotech, Inc.nuvilex_10k-ex1010.htm
EX-31.2 - CERTIFICATION - PharmaCyte Biotech, Inc.nuvilex_10k-ex3102.htm
EX-21.1 - LIST OF SUBSIDIARIES - PharmaCyte Biotech, Inc.nuvilex_10k-ex2101.htm
EX-10.1 - LICENSE AGREEMENT - PharmaCyte Biotech, Inc.nuvilex_10k-ex1001.htm
EX-10.4 - MASTER SERVICES AGREEMENT - PharmaCyte Biotech, Inc.nuvilex_10k-ex1004.htm
EX-31.1 - CERTIFICATION - PharmaCyte Biotech, Inc.nuvilex_10k-ex3101.htm
EX-10.7 - MASTER CONSULTANCY AGREEMENT - PharmaCyte Biotech, Inc.nuvilex_10k-ex1007.htm
EXCEL - IDEA: XBRL DOCUMENT - PharmaCyte Biotech, Inc.Financial_Report.xls
EX-32.2 - CERTIFICATION - PharmaCyte Biotech, Inc.nuvilex_10k-ex3202.htm
EX-10.2 - AMENDMENT TO LICENSE AGREEMENNT - PharmaCyte Biotech, Inc.nuvilex_10k-ex1002.htm

EXHIBIT 32.1

 

WRITTEN STATEMENT
PURSUANT TO
18 U.S.C. SECTION 1350

 

In connection with Annual Report of Nuvilex and its subsidiaries (“Company”) on Form 10-K for the year ended April 30, 2014 as filed with the Securities and Exchange Commission on the date hereof (“Report”), the undersigned, Kenneth L. Waggoner, Chief Executive Officer of the Company, certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

 

(1) The Report fully complies with the requirements of Section 13a-14(b) or 15d-14(b) of the Securities Exchange Act of 1934, as amended; and

 

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

 

Dated: August 1, 2014   By: /s/ Kenneth L. Waggoner                    
      Name:  Kenneth L. Waggoner
      Title:    Chief Executive Officer

 

 

A signed original of this written statement required by Section 906 of the Sarbanes Oxley Act of 2002 has been provided to the Company and will be retained by the Company and will be furnished to the SEC or its staff upon request.  This exhibit is not “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 but is instead furnished as provided by applicable rules of the SEC.

PharmaCyte Biotech, Inc. Reports

Also read